Terms: = Gastric cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Prognosis
13 results:
1. Predictive Value of Two Polymorphisms of ercc2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in gastric cancer Patients: A Meta-Analysis.
Li M; Zhao Y; Zhao E; Wang K; Lu W; Yuan L
Dis Markers; 2018; 2018():3947626. PubMed ID: 30581498
[TBL] [Abstract] [Full Text] [Related]
2. Polymorphisms of multiple genes involved in NER pathway predict prognosis of gastric cancer.
Liu J; Deng N; Xu Q; Sun L; Tu H; Wang Z; Xing C; Yuan Y
Oncotarget; 2016 Jul; 7(30):48130-48142. PubMed ID: 27340861
[TBL] [Abstract] [Full Text] [Related]
3. Genetic variability of ERCC1 and ercc2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer.
Zheng DL; Tang GD; Chen YN; Zhang T; Qin MB
Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173253
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic value of ERCC1 and ercc2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract] [Full Text] [Related]
5. Genetic variability of ERCC1 and ercc2 influences treatment outcomes in gastric cancer.
Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX
Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397
[TBL] [Abstract] [Full Text] [Related]
6. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract] [Full Text] [Related]
7. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract] [Full Text] [Related]
8. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
[TBL] [Abstract] [Full Text] [Related]
9. ERCC1 and ercc2 variants predict survival in gastric cancer patients.
Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY
PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723
[TBL] [Abstract] [Full Text] [Related]
10. A genetic variant in ercc2 is associated with gastric cancer prognosis in a Chinese population.
Chu H; Gu D; Xu M; Xu Z; Gong Y; Gong W; Tang Y; Zhou J; Tong N; Zhang Z; Chen J; Wang M
Mutagenesis; 2013 Jul; 28(4):441-6. PubMed ID: 23680703
[TBL] [Abstract] [Full Text] [Related]
11. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract] [Full Text] [Related]
12. Possible associations of APE1 polymorphism with susceptibility and HOGG1 polymorphism with prognosis in gastric cancer.
Canbay E; Agachan B; Gulluoglu M; Isbir T; Balik E; Yamaner S; Bulut T; Cacina C; Eraltan IY; Yilmaz A; Bugra D
Anticancer Res; 2010 Apr; 30(4):1359-64. PubMed ID: 20530453
[TBL] [Abstract] [Full Text] [Related]
13. Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of xpd, XRCC3 and UGT1A1 polymorphisms.
Font A; Salazar R; Maurel J; Taron M; Ramirez JL; Tabernero J; Gallego R; Casado E; Manzano JL; Carcereny E; Guix M; Fernández-Llamazares J; Rosell R
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1075-83. PubMed ID: 18335219
[TBL] [Abstract] [Full Text] [Related]
